CLEVELAND, June 21, 2018 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that University
University of Wisconsin Carbone Cancer Center helped pioneer the field of MR image-guided radiation therapy when they became the second hospital in the world to install the MRIdian System in the summer of 2014. Over the years they have treated hundreds of patients for indications including cancers of the breast, liver, lung, pancreas and esophagus. With its new MRIdian Linac, the hospital gains significant improvements such as greater treatment efficiency and sharper beams, with all the clinical benefits of real-time MRI-targeting, tracking and adaptive therapy. In addition to greater targeting precision, MRIdian Linac delivers radiation dose up to three times faster than the previous generation MRIdian system.
"With MRI-guidance we can see the impact our radiation therapy will have, and most importantly, how this affects our patients," said Michael Bassetti, M.D., assistant professor of human oncology at the University of Wisconsin Carbone Cancer Center. "We no longer have to assume what's happening inside the patient during treatment – we can actually watch the changes in real-time and respond accordingly."
"Tumors often move throughout the breathing cycle, and internal organs change shape and position daily,'' said John Bayouth, Ph.D., professor of human oncology and chief of medical physics at the University of Wisconsin Carbone Cancer Center. "Real-time MRI-guidance provides a novel way to manage the changing patient. This also helps us decrease radiation exposure to nearby healthy tissue and organs at risk during treatment."
ViewRay®, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose built to address specific challenges, including beam distortion, skin toxicity, and other concerns that may potentially arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. These statements are subject to risks and uncertainties that could cause future results to differ materially from those referenced. Forward looking statements include the potential for reduced risk, more effective radiation dose, improved targeting precision and transformative visualization and clinical outcomes. Given these uncertainties, the reader is advised not to place any undue reliance on any forward-looking statements. Additional risk factors include, among others, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates and overall market conditions. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents ViewRay files with the SEC available at www.sec.gov.
View original content:http://www.prnewswire.com/news-releases/university-of-wisconsin-begins-patient-treatments-with-viewrays-mridian-linac-300670021.html
SOURCE ViewRay, Inc.
Subscribe to our Free Newsletters!
Pneumonitis usually refers to inflammation of lung tissue due to various non-infective causes such ...
Fremanezumab-vfrm is used as a preventive treatment for a migraine headache in adult patients. It ...
DOOR syndrome is a rare genetic disorder marked by deafness, short or absent fingernails, abnormal ...View All